NASDAQ:ATBPD

Antibe Therapeutics Competitors

$3.57
+0.01 (+0.28 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.45
Now: $3.57
$3.67
50-Day Range
$3.13
MA: $3.84
$4.34
52-Week Range
$2.64
Now: $3.57
$3.50
Volume42,515 shs
Average Volume29,710 shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.57

Competitors

Antibe Therapeutics (NASDAQ:ATBPD) Vs. BPMC, SDGR, GLPG, BHVN, SAGE, and HCM

Should you be buying ATBPD stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Antibe Therapeutics, including Blueprint Medicines (BPMC), Schrödinger (SDGR), Galapagos (GLPG), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), and Hutchison China MediTech (HCM).

Antibe Therapeutics (NASDAQ:ATBPD) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk and Volatility

Antibe Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Antibe Therapeutics and Blueprint Medicines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics0000N/A
Blueprint Medicines06812.67

Blueprint Medicines has a consensus price target of $112.40, suggesting a potential upside of 18.07%. Given Blueprint Medicines' higher probable upside, analysts plainly believe Blueprint Medicines is more favorable than Antibe Therapeutics.

Valuation and Earnings

This table compares Antibe Therapeutics and Blueprint Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14
Blueprint Medicines$66.51 million82.96$-347,690,000.00($7.27)-13.09

Antibe Therapeutics has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe Therapeutics-273.96%-176.23%-106.91%
Blueprint Medicines41.08%43.72%33.35%

Summary

Blueprint Medicines beats Antibe Therapeutics on 9 of the 12 factors compared between the two stocks.

Antibe Therapeutics (NASDAQ:ATBPD) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares Antibe Therapeutics and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe Therapeutics-273.96%-176.23%-106.91%
Schrödinger-19.92%-7.25%-5.33%

Insider and Institutional Ownership

41.3% of Schrödinger shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Antibe Therapeutics and Schrödinger, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics0000N/A
Schrödinger01302.75

Schrödinger has a consensus price target of $85.50, suggesting a potential upside of 9.76%. Given Schrödinger's higher probable upside, analysts plainly believe Schrödinger is more favorable than Antibe Therapeutics.

Valuation and Earnings

This table compares Antibe Therapeutics and Schrödinger's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14
Schrödinger$85.54 million63.76$-24,570,000.00N/AN/A

Antibe Therapeutics has higher earnings, but lower revenue than Schrödinger.

Summary

Schrödinger beats Antibe Therapeutics on 7 of the 9 factors compared between the two stocks.

Antibe Therapeutics (NASDAQ:ATBPD) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Antibe Therapeutics and Galapagos' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14
Galapagos$1.00 billion5.17$167.83 million$5.4614.50

Galapagos has higher revenue and earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antibe Therapeutics and Galapagos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe Therapeutics-273.96%-176.23%-106.91%
Galapagos-70.67%-11.78%-5.58%

Insider & Institutional Ownership

11.2% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Antibe Therapeutics and Galapagos, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics0000N/A
Galapagos210502.18

Galapagos has a consensus price target of $143.7273, suggesting a potential upside of 81.59%. Given Galapagos' higher probable upside, analysts clearly believe Galapagos is more favorable than Antibe Therapeutics.

Volatility & Risk

Antibe Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Summary

Galapagos beats Antibe Therapeutics on 11 of the 13 factors compared between the two stocks.

Antibe Therapeutics (NASDAQ:ATBPD) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility & Risk

Antibe Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Antibe Therapeutics and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe Therapeutics-273.96%-176.23%-106.91%
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Valuation and Earnings

This table compares Antibe Therapeutics and Biohaven Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.82

Antibe Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Antibe Therapeutics and Biohaven Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics0000N/A
Biohaven Pharmaceutical021002.83

Biohaven Pharmaceutical has a consensus price target of $96.4545, suggesting a potential upside of 29.64%. Given Biohaven Pharmaceutical's higher probable upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than Antibe Therapeutics.

Sage Therapeutics (NASDAQ:SAGE) and Antibe Therapeutics (NASDAQ:ATBPD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sage Therapeutics and Antibe Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sage Therapeutics08802.50
Antibe Therapeutics0000N/A

Sage Therapeutics presently has a consensus target price of $87.0625, suggesting a potential upside of 16.64%. Given Sage Therapeutics' higher probable upside, research analysts clearly believe Sage Therapeutics is more favorable than Antibe Therapeutics.

Risk & Volatility

Sage Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Profitability

This table compares Sage Therapeutics and Antibe Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sage Therapeutics-7,706.84%-63.81%-56.64%
Antibe Therapeutics-273.96%-176.23%-106.91%

Valuation and Earnings

This table compares Sage Therapeutics and Antibe Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sage Therapeutics$6.87 million634.30$-680,240,000.00($13.38)-5.58
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14

Antibe Therapeutics has higher revenue and earnings than Sage Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sage Therapeutics beats Antibe Therapeutics on 6 of the 11 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Antibe Therapeutics (NASDAQ:ATBPD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Hutchison China MediTech and Antibe Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Antibe Therapeutics0000N/A

Hutchison China MediTech presently has a consensus price target of $40.00, indicating a potential upside of 36.75%. Given Hutchison China MediTech's higher possible upside, research analysts plainly believe Hutchison China MediTech is more favorable than Antibe Therapeutics.

Risk & Volatility

Hutchison China MediTech has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares Hutchison China MediTech and Antibe Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Antibe Therapeutics-273.96%-176.23%-106.91%

Valuation and Earnings

This table compares Hutchison China MediTech and Antibe Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million20.79$-106,020,000.00($0.80)-36.56
Antibe Therapeutics$7.51 million183.97$-14,540,000.00($0.50)-7.14

Antibe Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Hutchison China MediTech beats Antibe Therapeutics on 8 of the 12 factors compared between the two stocks.


Antibe Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90+0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64+1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69+0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94+2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03+5.8%$3.58 billionN/A-20.81Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59+0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07+1.7%$3.42 billion$136.47 million-12.72News Coverage
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15+0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54+1.3%$3.25 billion$36.13 million-69.46Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87+0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69+2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60+4.2%$3.04 billionN/A-56.02Insider Selling
MorphoSys logo
MOR
MorphoSys
0.3$22.65+2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34+0.5%$2.91 billion$901.90 million-24.11Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64+1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07+5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46+5.3%$2.75 billion$260.98 million-357.67Analyst Downgrade
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00+0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39+0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77+0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81+1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22+3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26+5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73+0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57+2.6%$2.35 billion$33.94 million-88.91Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13+5.6%$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22+0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96+1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68+0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15+0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77+1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44+1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02+0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22+3.5%$1.94 billion$410,000.00-5.92Analyst Report
Gap Down
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69+4.6%$1.91 billionN/A-25.40Increase in Short Interest
Gap Down
MacroGenics logo
MGNX
MacroGenics
1.2$31.83+2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73+3.2%$1.90 billion$34.51 million-17.72
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.